

Postoperative proton therapy for pancreatic cancer patients enrolled on the Proton Collaborative Group (PCG) registry



Romaine Nichols¹, Christopher Morris¹, Megan Dunn², Kiran Prabhu³, Lisa McGee⁴, William Hartsell⁴, Oren Cahlon⁵, Smith Apisarnthanarax⁶, Carlos Vargas⁶

¹University of Florida, Radiation Oncology, Jacksonville- Florida 32206, USA.

²Proton Cooperative Group, Research, Warrenville- Illinois 60555, USA.

³Procure Proton Therapy Center, Radiation Oncology, Oklahoma City- Oklahoma 73142, USA.

⁴Northwestern Medicine Chicago Proton Center, Radiation Oncology, Warrenville- Illinois 60555, USA.

⁵Procure Proton Therapy Center - New Jersey, Radiation Oncology, Somerset- New Jersey 08873, USA.

⁶Seattle Cancer Care Alliance Proton Therapy Center, Radiation Oncology, Seattle- Washington 98133, USA.

⁷Mayo Clinic, Radiation Oncology, Phoenix- Arizona 85054, USA.

Background

The PCG registry is a multicenter registry for patients receiving proton therapy for various malignancies. The current abstract reviews the outcomes for patients receiving postoperative proton therapy for resected pancreatic cancer.

Methods


From 2/2013 to 6/2015 12 patients with resected pancreatic adenocarcinoma received postoperative proton therapy. The current study reviews the pretreatment characteristics and outcomes of these patients.

Results

Median age - 72 years (range 52 to 79); Males 8, Females 4; T Stage - T2-3, T3-8, T4-1; N Stage - N1-10, N0-0; Margin Status - Close-5, Positive-3, Negative-4; Surgical approach - open-10, laparoscopic 2; Operations performed - standard pancreaticoduodenectomy-7, pylorus sparing pancreaticoduodenectomy- 4, total pancreatectomy-1; Median lymph nodes taken-19.50 (range 11 to 72); Median lymph nodes positive-2 (range 0 to 7); PNI positive-9, PNI unknown-3; LVI positive-6, LVI negative-3, LVI unknown-3; Median tumor size - 3cm (range 2.2 to 6.2); Median dose delivered - 50.51Gy(RBE) (range 27.88 to 54.00); Median treatment duration - 38 calendar days (range 25 to 48); One patient died during treatment. Only one patient's treatment was protracted by more than 5 days. Median available follow up is 0.9 years (range 0.07 to 1.7 years); 1 year survival 54%

Conclusion

Postoperative proton therapy after pancreatectomy was well tolerated without significant toxicity or treatment interruption.



SITE	Gender	Age	Path	Stage	Margins	Nodes	RT start	Dose	Fraction	Days	Chemo during RT	STATUS
OKC	Male	67	Aca PD	T3N1	1mm	2/11	03/25/2014	50.5	1	28	38Capecitabine	In Follow-Up
Chicago	Female	61	Aca PD	T4N1	Positive	3/19	03/04/2013	50.5	1	28	37Inf-5FU	Death
Chicago	Male	72	Aca	T3N1	2.2mm	3/72	11/14/2013	50.5	1	28	405FU	Death
Chicago	Female	66	Aca PD	T2N1	Negative	1/24	01/20/2014	50.5	1	28	385FU	In Follow-Up
Chicago	Male	72	Aca	T3N0	1mm	0/18	04/23/2014	45.3	8	25	35Capecitabine	In Follow-Up
Chicago	Female	77	Aca MD	T2N1	Positive	2/25	09/22/2014	27.8	8	17	25none	Death
Chicago	Male	63	Aca MD	T2N1	1mm	3/23	09/18/2014	44.0	4	27	365FU	In Follow-Up
Chicago	Male	76	Aca MD	T3N1	1mm	7/32	06/29/2015	45.6	4	28	425FU	In Follow-Up
NJ	Female	79	Aca PD	T3N1	Negative	2/12	08/19/2013	50.5	1	28	39Capecitabine	Death
NJ	Male	77	Aca PD	T3N0	Negative	0/13	06/02/2014	50.5	1	28	38Capecitabine	In Follow-Up
NJ	Male	52	Aca PD	T3N1	Positive	4/14	07/09/2014	48.6	27	37	Abrax, Gem, Cape	Death
			Aca MD		Negative		1/28/201					In Follow-Up